Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR1016C vs BR1016D (Sacubitril/Valsartan) in Healthy Volunteers
NCT05102266Phase 1Completed
- Sponsor
- Boryung
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacubitril + valsartan in chronic heart failure (CHF), sponsored by Boryung. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Started Oct 2021; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT05102266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102266.